Dr. Hans T. Schambye, MD, Ph.D is a Co-Founder of Galecto Biotech AB and serves as Chief Executive Officer. Dr. Schambye served as Chief Executive Officer of ReceptIcon since joining it in 2006 until 2009. He served as Chief Executive Officer of Gastrotech Pharma A/S from 2004 to 2006. Dr. Schambye has substantial experience in managing Biotech companies. He served as Chief Executive Officer of Rose Pharma A/S since 2004 and as its Senior Vice President of Research and Development since March 2004. He served as Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a U.S Biotech company. He co-founded ProFound Pharma A/S in 1999. He served as a Project Manager at Novo Nordisk. He also served as Hospital Doctor mainly within gastroenterology at Novo. He is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Dr. Schambye had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. He served as Chairman of Rose Pharma A/S. He served as Chairman of Forward Pharma A/S and also served as its Director. Dr. Schambye was Postdoctoral fellow at Stanford University. He holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.  

    His research interest are Biology and Pharmacology